From the Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran; and.
Rajaie Cardiovascular, Medical, and Research Center; Iran University of Medical Sciences, Tehran, Iran.
Crit Pathw Cardiol. 2021 Mar 1;20(1):53-55. doi: 10.1097/HPC.0000000000000228.
In the Coronavirus Disease 2019 (COVID-19) pandemic, the appropriate reperfusion strategy in patients with ST-segment elevation myocardial infarction (STEMI) is unclear.
This retrospective single-center study consecutively enrolled patients who presented with STEMI and scheduled for primary percutaneous coronary intervention (PPCI) during the outbreak of COVID-19. Due to the delay in the reporting of the polymerase chain reaction test results, our postprocedural triage regarding COVID-19, followed by the isolation strategy, was based on lung computerized tomography scan results.
Forty-eight patients with STEMI referred to our center. PPCI was done for 44 (91%) of these patients. The mean symptom-to-device time was 490.93 ± 454.608 minutes, and the mean first medical contact-to-device time was and 154.12 ± 36.27 minutes. Nine (18%) patients with STEMI were diagnosed as having typical/indeterminate features indicating COVID-19 involvement. During hospitalization, 1 (2.0%) patient died of cardiogenic shock. The study population was followed for 35.9 ± 12.7 days. Two patients expired in another centers due to COVID-19. No cardiac catheterization laboratory staff members were infected by COVID-19 during the study period.
Our small report indicates that by taking the recommended safety measures and using appropriate PPE, we can continue PPCI as the main reperfusion strategy safely and effectively.
在 2019 年冠状病毒病(COVID-19)大流行期间,ST 段抬高型心肌梗死(STEMI)患者的适当再灌注策略尚不清楚。
这是一项回顾性单中心研究,连续纳入了在 COVID-19 爆发期间出现 STEMI 并计划进行直接经皮冠状动脉介入治疗(PPCI)的患者。由于聚合酶链反应检测结果报告的延迟,我们对 COVID-19 的术后分类以及随后的隔离策略是基于肺部计算机断层扫描结果。
有 48 例 STEMI 患者被转至我们中心。对其中 44 例(91%)患者进行了 PPCI。平均症状至器械时间为 490.93±454.608 分钟,平均首次医疗接触至器械时间为 154.12±36.27 分钟。9 例(18%)STEMI 患者被诊断为具有提示 COVID-19 参与的典型/不确定特征。住院期间,1 例(2.0%)患者死于心源性休克。该研究人群的随访时间为 35.9±12.7 天。另外 2 例患者在其他中心因 COVID-19 去世。在研究期间,没有心脏导管室工作人员感染 COVID-19。
我们的小报告表明,通过采取建议的安全措施和使用适当的个人防护设备,我们可以安全有效地继续将 PPCI 作为主要再灌注策略。